The use of obesity drugs increased considerably last year
Coil|In five years, the number of obesity drugs has increased more than 11 times. According to Kela, use can be expensive for society.
Obesity The use increased dramatically last year, says Kela in a news release. According to it, over 75,000 Finns used obesity or weight management drugs. The number of users increased by a fifth of the other year.
In five years, the number of users has increased more than 11 times.
The most commonly used drug was Semaglutide, which is almost entirely self -sufficient. Only some of the current obesity drugs may receive drug reimbursement for obesity treatment.
Semaglutid The number of users rose from about 48,000 to a quarter to about 60,000 from the other year to last year.
Many do not discuss the introduction of an obesity medicine with your doctor. The announcement states that, according to a Danish survey, more than 40 % of those who purchased Semaglutid for weight management had not discussed the length of the treatment with the doctor.
According to the release, more than half will stop medication during the first year, even if permanent weight management requires long -term or permanent medication in the treatment of lifestyle.
If you stop using your obesity medicine, your weight will start to rise quickly, Kela’s docent Pia Pajunen says in the bulletin.
Obesity According to Kela, they are currently expensive, which is expected to limit their use. For example, a monthly dose of a Wegovy obesity medicine with a recommended maintenance dose, according to Kela, cost nearly € 300 in May.
In the future, the use and costs of obesity drugs may be influenced by the decisions of their reimbursement.
“The use of obesity drugs is growing at a tremendous pace and in the future it can be expensive for society in the future. At the same time, not treating obesity also causes significant costs and health damage,” says Kela Senior Research Heini Kari in the bulletin.
According to Kela, the use of obesity drugs may expand, for example, to the treatment of type 2 diabetes, cardiovascular disease and kidney disease, as several obesity drugs have been found to be useful in their treatment.
